Comparison of Dydrogesterone and Micronized Progesterone Treatments in the Treatment of Threatened Miscarriage.
NCT ID: NCT05542797
Last Updated: 2022-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
140 participants
INTERVENTIONAL
2022-10-31
2024-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Threatened Miscarriage
NCT02128685
Vaginal Progesterone for Treatment of Threatened Miscarriage
NCT02690129
Oral Progesterone for Prevention of Miscarriage in Threatened Abortion
NCT04788108
Estradiol Pretreatment With Misoprostol in Second Trimester Miscarriage
NCT03479879
Gemeprost Versus Dinoprostone in First Trimester Miscarriages
NCT05342467
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Micronised progesterone
Micronized progesterone will be given to 70 pregnant women with threated miscarriage.
Duphastone
dydrogesterone hormone
Dydrogesterone
Dydrogesterone will be given to 70 pregnant women with threated miscarriage.
Duphastone
dydrogesterone hormone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Duphastone
dydrogesterone hormone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
30 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Konya Meram State Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hasan Ali Inal, MD
obstetrics and gynecology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
351508
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.